Literature DB >> 20171768

Significance of JAK2 and TET2 mutations in myelodysplastic syndromes.

Eva Hellström-Lindberg1.   

Abstract

The pathogenesis of myelodysplastic syndromes involves a pattern of genetic, epigenetic, and immune-mediated mechanisms but little is known about what causes the specific disease features and promotes disease progression in the individual patient. The identification of JAK2 and MPL mutations, and more recently TET2, CBL and ASXL-1 mutations in these disorders provide a basis for increased understanding of disease biology and mechanisms behind progression. Such mutations are more commonly found in patients with a significant amount of marrow ring sideroblasts, and in patients belonging to the category of mixed myelodysplastic/myeloproliferative neoplasms, entities which are in focus for this review. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20171768     DOI: 10.1016/j.blre.2010.01.002

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  5 in total

1.  SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.

Authors:  Teresa Mortera-Blanco; Marios Dimitriou; Petter S Woll; Mohsen Karimi; Edda Elvarsdottir; Simona Conte; Magnus Tobiasson; Monika Jansson; Iyadh Douagi; Matahi Moarii; Leonie Saft; Elli Papaemmanuil; Sten Eirik W Jacobsen; Eva Hellström-Lindberg
Journal:  Blood       Date:  2017-06-20       Impact factor: 22.113

2.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Authors:  Anna M Jankowska; Hideki Makishima; Ramon V Tiu; Hadrian Szpurka; Yun Huang; Fabiola Traina; Valeria Visconte; Yuka Sugimoto; Courtney Prince; Christine O'Keefe; Eric D Hsi; Alan List; Mikkael A Sekeres; Anjana Rao; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

3.  Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.

Authors:  João Agostinho Machado-Neto; Fabiola Traina; Mariana Lazarini; Paula de Melo Campos; Katia Borgia Barbosa Pagnano; Irene Lorand-Metze; Fernando Ferreira Costa; Sara T Olalla Saad
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  TET2 Inhibits Differentiation of Embryonic Stem Cells but Does Not Overcome Methylation-Induced Gene Silencing.

Authors:  Louis Norman; Paul Tarrant; Timothy Chevassut
Journal:  Bone Marrow Res       Date:  2014-08-25

Review 5.  Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights.

Authors:  Saeid Shahrabi; Abbas Khosravi; Mohammad Shahjahani; Fakher Rahim; Najmaldin Saki
Journal:  Oncol Rev       Date:  2016-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.